Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
See our latest analysis for Zevra Therapeutics. At today's $8.33 share price, Zevra's recent pullback comes after a solid 90 day share price return and sits against a three year total shareholder return that still looks impressive despite a weaker five year record. This suggests momentum has cooled but not disappeared. If Zevra's swings have you rethinking your exposure to drug developers, this could be a good moment to explore other healthcare stocks that might better match your risk appetite. With analysts still seeing sizable upside and the shares trading at a steep estimated discount to intrinsic value, the key question now is clear: is Zevra undervalued, or is the market already pricing in its future growth? Compared with Zevra Therapeutics' last close at $8.33, the most widely followed narrative points to a much higher fair value, built on aggressive growth and margin assumptions. The launch strategy for MIPLYFFA is gaining traction, as evidenced by rapid U.S. patient
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics announces CFO transition [Seeking Alpha]Seeking Alpha
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/9/25 - Form 4
- 12/9/25 - Form 3
- 12/2/25 - Form 8-K
- ZVRA's page on the SEC website